Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study

Diabetologia
Jens OellgaardOluf Pedersen

Abstract

In type 2 diabetes mellitus, heart failure is a frequent, potentially fatal and often forgotten complication. Glucose-lowering agents and adjuvant therapies modify the risk of heart failure. We recently reported that 7.8 years of intensified compared with conventional multifactorial intervention in individuals with type 2 diabetes and microalbuminuria in the Steno-2 study reduced the risk of cardiovascular disease and prolonged life over 21.2 years of follow-up. In this post hoc analysis, we examine the impact of intensified multifactorial intervention on the risk of hospitalisation for heart failure. One hundred and sixty individuals were randomised to conventional or intensified multifactorial intervention, using sealed envelopes. The trial was conducted using the Prospective, Randomised, Open, Blinded Endpoints (PROBE) design. After 7.8 years, all individuals were offered intensified therapy and the study continued as an observational follow-up study for an additional 13.4 years. Heart-failure hospitalisations were adjudicated from patient records by an external expert committee blinded for treatment allocation. Event rates were compared using a Cox regression model adjusted for age and sex. Eighty patients were assigned to ...Continue Reading

References

Nov 1, 1972·Scandinavian Journal of Clinical and Laboratory Investigation·J Bröchner-Mortensen
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Apr 2, 2003·Annals of Internal Medicine·Tomas BerlUNKNOWN Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Sep 25, 2012·Heart Failure Clinics·Annayya R AroorJames R Sowers
Nov 6, 2012·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN ALTITUDE Investigators
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·John J V McMurrayMarc A Pfeffer
Aug 27, 2014·International Journal of Cardiology·Chaitanya MadamanchiMarschall S Runge
May 20, 2015·Clinical and Molecular Allergy : CMA·Carlo AgostiniEnrico Maggi
May 27, 2015·Lancet·Richard E Gilbert, Henry Krum
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Mar 11, 2016·Nature Reviews. Cardiology·Itamar Raz, Avivit Cahn
Mar 24, 2016·The New England Journal of Medicine·Kristian B FilionUNKNOWN CNODES Investigators
Apr 8, 2016·Nature Reviews. Cardiology·Dario Ummarino
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Apr 12, 2017·The Lancet. Diabetes & Endocrinology·Lars RydénRury R Holman
May 21, 2017·The American Journal of Medicine·Michael Lehrke, Nikolaus Marx
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Nov 17, 2017·Journal of the American College of Cardiology·Kevin S ShahGregg C Fonarow

❮ Previous
Next ❯

Citations

Jan 30, 2020·Circulation·Salim S ViraniUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Jan 29, 2020·Diabetes Care·Giulia FerranniniEle Ferrannini
May 20, 2020·Alcoholism, Clinical and Experimental Research·Karen HovhannisyanHanne Tønnesen
Jun 3, 2020·The Journal of Clinical Endocrinology and Metabolism·Silvio E InzucchiBernard Zinman
Aug 30, 2020·European Heart Journal·Jean-Philippe ColletUNKNOWN ESC Scientific Document Group
Jul 19, 2020·Cardiovascular Drugs and Therapy·Pappitha RajaDerek P Brazil
Sep 28, 2018·Current Cardiology Reports·Nikhil Bassi, Gregg C Fonarow
Feb 21, 2019·Therapeutic Advances in Endocrinology and Metabolism·Shazli AzmiRayaz A Malik
Apr 10, 2019·Current Vascular Pharmacology·Triantafyllos Didangelos, Konstantinos Kantartzis
Aug 23, 2018·Diabetologia·Sally M Marshall
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Nov 27, 2019·European Journal of Preventive Cardiology·Lars RydénLinda Mellbin
Nov 9, 2018·Current Diabetes Reports·Robert J ChiltonSon Pham
Nov 30, 2020·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Luiz Sérgio Fernandes de CarvalhoAndrei Carvalho Sposito
Jan 30, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraKumar Gaurav
Jul 14, 2019·Progress in Cardiovascular Diseases·Adam J NelsonNeha J Pagidipati
Apr 26, 2021·Diabetes Research and Clinical Practice·Paul ValensiErwan Donal
Aug 21, 2021·The Journal of Clinical Endocrinology and Metabolism·Jian-Jun LiuSu Chi Lim
Sep 4, 2020·Current Drug Safety·Anna Pietraszek
Oct 2, 2021·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Isabelle JohanssonFrancesco Cosentino
Mar 3, 2020·Diabetes Spectrum : a Publication of the American Diabetes Association·Manel Mata-CasesDídac Mauricio

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation

Clinical Trials Mentioned

NCT00320008

Software Mentioned

IC
STATA

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.